D0007 - Overall Survival Trends of Pancreatic Cancer, a Surveillance, Epidemiology and End Results (SEER) Population-Based Data (2002-2016)

Dina Elantably, MD¹, Abdul Rahman Al Armashi, MD², Faris Hammad, MD³, Anas Al Zubaidi, MD⁴, Akram Alkrekshi, MD^1
1MetroHealth Medical Center/Case Western Reserve University, Cleveland, OH; ²University Hospitals Case Western Reserve University, Cleveland, OH; ³St. Vincent Charity Medical Center, Cleveland, OH; ⁴Johns Hopkins University, Baltimore, MD

Introduction: Pancreatic cancer (PC) is the third leading cause of cancer-related deaths in the United States. The general 5-year survival rate for people with pancreatic cancer in the US is 11%. Survival rates and outcomes are based on many factors, including the specific stage of the disease when it is diagnosed. We conducted an evaluation of survival trends after PC diagnosis overall and by stage of the disease.

Methods: We performed a database query into the Surveillance, Epidemiology, and End Results (SEER) Program 17 registry. Between 2002 and 2016, we included individuals diagnosed with pancreatic cancer to evaluate 5-year survival trends. The results were observed using the Actuarial - Ederer II method for cumulative expected survival (absence of other causes of death).

Results: Cancer stage was an important factor in explaining variability in 5-year survival. The SEER localized stage of pancreatic cancer showed an improvement of the overall 5-year survival between 2012 and 2016 (38.8%) compared to those between 2002 and 2006 (21%). The Regional stage also showed an improvement of the overall 5-year survival between 2012 and 2016 (12.9%) compared to those between 2002-2006 (8.3%). However, in the distant stage, the 5-year overall survival showed a minimal improvement from 2 % to 2.8%.

Discussion: From 2002 to 2016, the overall survival of patients with PC has improved across all the SEER stages, with a remarkable improvement by 17.8% in the localized stage and 4.6% in the regional stage. This improvement may reflect the enhanced diagnostic and treatment modalites. The negligible improvement in the distant stage is partly explained by the poor overall prognosis and the use of only supportive care.



Disclosures:


Dina Elantably, MD¹, Abdul Rahman Al Armashi, MD², Faris Hammad, MD³, Anas Al Zubaidi, MD⁴, Akram Alkrekshi, MD¹. D0007 - Overall Survival Trends of Pancreatic Cancer, a Surveillance, Epidemiology and End Results (SEER) Population-Based Data (2002-2016), ACG 2022 Annual Scientific Meeting Abstracts. Charlotte, NC: American College of Gastroenterology.